Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study.
Ivan A MolodtsovEvgenii KegelesAlexander N MitinOlga MityaevaOksana E MusatovaAnna E PanovaMikhail V PashenkovIuliia O PeshkovaAlmaqdad AlsalloumWalaa AsaadAnna S BudikhinaAlexander S DeryabinInna V DolzhikovaIoanna N FilimonovaAlexandra N GrachevaOxana I IvanovaAnastasia KizilovaViktoria V KomogorovaAnastasia KomovaNatalia I KompantsevaEkaterina KucheryavykhDenis А LagutkinYakov A LomakinAlexandra V MaleevaElena V MaryukhnichAfraa MohammadVladimir V MuruginNina E MuruginaAnna NavoikovaMargarita F NikonovaLeyla A OvchinnikovaYana PanarinaNatalia V PineginaDaria M PotashnikovaElizaveta V RomanovaAleena A SaidovaNawar SakrAnastasia G SamoilovaYana SerdyukNaina T ShakirovaNina I SharovaSaveliy A SheetikovAnastasia F ShemetovaLiudmila V ShevkovaAlexander V ShpektorAnna TrufanovaAnna V TvorogovaValeria M UkrainskayaAnatoliy S VinokurovDaria A VorobyevaKsenia V ZornikovaGrigory A EfimovMusa R KhaitovIlya A KofiadiAlexey A KomissarovDenis Y LogunovNelli B NaigovzinaYury P RubtsovIrina A VasilyevaPavel Y VolchkovElena VasilievaPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
We found that the contribution of the virus-specific antibodies to protection against SARS-CoV-2 infection is more pronounced than that of the T cells. The data on the virus-specific IgG titers may be instructive for making decisions in personalized healthcare and public anti-COVID-19 policies. Clinical Trials Registration. NCT04898140.